The Fine Chemical Benchmarking Service analyses the fine chemical industry. Within that industry it focuses on the largest and most important segment: fine chemicals for the pharmaceutical and agrochemical industries (the life science industries).
The service is provided on annual subscription basis, and consists of three parts. The updating frequency is once a year for Part 1 and Part 3; twice a year for Part 2. Typically the data of the previous versions also remain part of the new document, which gives easy access to historic developments of the companies and markets involved. Data are going back to 1999 for Parts 1 and 2, and as far as 1990 for some of the companies in Part 3.
Part 1 provides an analysis of the current status and dynamics of the pharmaceutical industry from a fine chemical point of view.
The segments in the development phase of the pharmaceutical product life cycle are analysed in terms of
- Total value of each of the segments
- ‘Fine chemical’ value of each of the segments
- Cost and success rate of pharmaceutical development
- Total pharmaceutical R&D expenditure
- R&D expenditure breakdown by type
- Chemical versus other expenditure in pharmaceutical R&D
The rapid changes in the screening and discovery phase of drug development as a result of genomics, combinatorial chemistry and ultra high throughput screening are described.
